Overview

Departments

Rheumatology

Medicine

Clinical Interests
  • IgG4-related systemic disease
  • Giant cell arteritis
  • Aortitis
  • ANCA-associated vasculitis
  • Cutaneous vasculitis
  • Gout and pseudogout
  • Behcet's syndrome
  • Dermatomyositis
  • Rheumatoid arthritis
  • Lupus
Medical Education
  • MD, Harvard Medical School
  • Residency, The Johns Hopkins Hospital
  • Fellowship, UC San Francisco
Board Certifications
  • Internal Medicine
  • Rheumatology
Foreign Languages
  • German
Locations
  • Boston: Massachusetts General Hospital
Patient Gateway
Yes, learn more
Insurances Accepted
  • Aetna Health Inc.
  • Beech Street
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • Cigna (PAL #'s)
  • Fallon Community HealthCare
  • Great-West Healthcare (formally One Health Plan)
  • Harvard Pilgrim Health Plan - ACD
  • Harvard Pilgrim Health Plan - PBO
  • Health Care Value Management (HCVM)
  • Humana/Choice Care PPO
  • MassHealth
  • Medicare
  • Medicare - ACD
  • Neighborhood Health Plan - ACD
  • Neighborhood Health Plan - PBO
  • OSW - Maine
  • OSW - New Hampshire
  • OSW - Rhode Island
  • Private Health Care Systems (PHCS)
  • Senior Whole Health
  • TriCare
  • Tufts Health Plan
  • Unicare
  • United Healthcare (non-HMO) - ACD
  • United Healthcare (non-HMO) - PBO

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.

Patient Age Group
Adult
Gender
Male

Edit Profile

Biography

Research: I co-founded the Vasculitis Center at Johns Hopkins University and directed a multi-center, randomized clinical trial in Wegener's granulomatosis. The results of this trial were published in The New England Journal of Medicine (2005). I am currently the Co-PI of a second multi-center clinical trial in ANCA-associated vasculitis: Rituximab in ANCA-Associated Vasculitis HRAVe). The primary results of this trial were recently published in The New England Journal of Medicine (2010).

My most current research interest pertains to an emerging disease known as IgG4-related systemic disease (IgG4-RSD). My research group at the MGH made the seminal observation that rituximab therapy leads to the targeted reduction of the IgG4 subclass of immunoglobulins in this disorder.

Teaching: I gave the Sir James Cameron Lecture at the Royal College of Physicians (Edinburgh) in 2003. I delivered the Dunlop-Dottridge Lecture at the Canadian Rheumatology Association (2007), and gave the Woodbury Lecture at Dalhousie University in 2010.

Edit Profile

Research & Publications

Research Summary

Research: I co-founded and directed the Vasculitis Center at Johns Hopkins University, where I directed a multi-center, randomized clinical trial in Wegener's granulomatosis. The results of this trial were published in The New England Journal of Medicine (2005). This trial, the first-ever NIH-funded randomized clinical trial in vasculitis, paved the way for subsequent trials and investigations in vasculitis on an international scale.

I am currently the Co-PI of a second multi-center clinical trial in ANCA-associated vasculitis: Rituximab in ANCA-Associated Vasculitis (RAVe). This trial, which includes 8 centers in both the United States and Europe, is sponsored by the Immune Tolerance Network (NIAID). The primary results of this trial were recently published in The New England Journal of Medicine (2010).

My most current research interest pertains to an emerging disease known as IgG4-related systemic disease (IgG4-RSD). My research group at the MGH made the seminal observation that rituximab therapy leads to the targeted reduction of the IgG4 subclass of immunoglobulins in this disorder, with maintenance of normal levels of other IgG subclasses.

Publications

Selected Research Investigation Publications

25. The WGET Research Group (Principal Investigator and Chairman, Writing Committee: Stone JH). Etanercept Plus Standard Therapy for Wegener's Granulomatosis. N Engl J Med 2005;352(4):351-61.

Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab therapy leads to swift decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis & Rheumatism 2010; 62:1755-62.

68. Stone JH, Merkel PA, Spiera R et al. Rituximab Compared With Cyclophosphamide For Remission Induction In ANCA-Associated Vasculitis. N Engl J Med 2010; 363:221-32.

Ramos-Casals M, Stone JH, Cid MC, Bosch X. The Cryoglobulinaemias. The Lancet (In press, February, 2011).

Edit Profile

News & Events

Contact

Rheumatology Associates
55 Fruit Street
Boston MA, 02114-2696
Phone: 617-726-7938
Fax: 617-643-1274

Edit Profile